If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Merchandising == The Guinness Storehouse at St. James's Gate Brewery in Dublin is the most popular tourist attraction in Ireland (attracting over 1.7 million visitors in 2019) where a self-guided tour includes an account of the ingredients used to make the stout and a description of how it is made. Visitors can sample the smells of each Guinness ingredient in the Tasting Rooms, which are coloured with a unique lighting design that emits Guinness's gold and black branding. The Guinness Book of Records started as a Guinness marketing giveaway, based on an idea of its then Managing Director, Sir Hugh Beaver. Its holding company, Guinness World Records Ltd, was owned by Guinness plc, subsequently Diageo, until 2001. The 2025 drama series House of Guinness deals with the growth of the business in 19th century Ireland.
military states that one of its soldiers was killed and another soldier was slightly wounded in north of Iraq the previous day, "during a controlled detonation of unexploded ordnance from a downed Iranian one-way attack drone." 2026 FIFA World Cup final: Spain beat defending champions Argentina 1–0 after extra time at the MetLife Stadium in East Rutherford, New Jersey to win a second FIFA World Cup title. July 20 – 2026 Iran war: The U.S. military conducts a ninth consecutive night of strikes on Iranian targets, which President Trump says are retaliation for the deaths of three American soldiers. July 21 The US announces a trade agreement with Jordan. The US begins allowing direct flights between the US and Lebanon for the first time since 1985. OpenAI reveals that an autonomous artificial intelligence agent powered by its models escaped a controlled testing environment and compromised the computer systems of Hugging Face while attempting to obtain answers to a cybersecurity evaluation. OpenAI describes it as an "unprecedented cyber incident". July 22 2026 Iran war: The US conducts its 11th consecutive night of strikes in Iran. Trump states that the US would strike and destroy Iran's bridges and power plants for each ship it attacks in the Strait of Hormuz. The U.S. signs a deal with Saudi Arabia to develop a civilian nuclear program in the country. Trump demands that Saudi Arabia join the Abraham Accords so that the agreement will take effect. July 23 2026 Iran war: The US conducts its 12th consecutive night of strikes in Iran.
=== Valve === Faliszek's and Wolpaw's writings led to them being hired by Valve circa 2005. Along with Wolpaw and Marc Laidlaw, Faliszek helped to create the storylines for the Half-Life and Portal series, along with having personally written the story for Left 4 Dead. He was also involved with Valve's work in virtual reality (VR) through the HTC Vive. In May 2017, Faliszek announced that after twelve years with Valve, he had left the company earlier in the year to work on unannounced projects.
===== Triple combination ===== The combination of metformin with dapagliflozin and saxagliptin is available in the United States as Qternmet XR. The combination of metformin with pioglitazone and glibenclamide is available in India as Accuglim-MP, Adglim MP, and Alnamet-GP; and in the Philippines as Tri-Senza. The combination of metformin with pioglitazone and lipoic acid is available in Turkey as Pional.
Sources: en.wikipedia.org
=== General and cited references === National Burn Repository 2012 Report (PDF). Dataset Version 8.0. Chicago: American Burn Association. 2012. Archived from the original (PDF) on 3 March 2016. Retrieved 20 April 2013.
=== Australia === A study by the Australian National University published in 2022 for Food Standards Australia New Zealand estimated there are 4.67 million cases of food poisoning in Australia each year that result in 47,900 hospitalisations, 38 deaths and a cost to the economy of $2.1 billion. A previous study using different methodology and published in November 2014, found in 2010 that there were an estimated 4.1 million cases of foodborne gastroenteritis acquired in Australia on average each year, along with 5,140 cases of non-gastrointestinal illness. The main causes were norovirus, pathogenic Escherichia coli, Campylobacter spp. and non-typhoidal Salmonella spp., although the causes of approximately 80% of illnesses were unknown. Approximately 25% (90% CrI: 13%–42%) of the 15.9 million episodes of gastroenteritis that occur in Australia were estimated to be transmitted by contaminated food. This equates to an average of approximately one episode of foodborne gastroenteritis every five years per person. Data on the number of hospitalisations and deaths represent the occurrence of serious foodborne illness. Including gastroenteritis, non-gastroenteritis and sequelae, there were an estimated annual 31,920 (90% CrI: 29,500–35,500) hospitalisations due to foodborne illness and 86 (90% CrI: 70–105) deaths due to foodborne illness circa 2010. This study concludes that these rates are similar to recent estimates in the US and Canada. A main aim of this study was to compare if foodborne illness incidence had increased over time.
=== Desalination === Treatment must also take into account the type of water the wood was found in. Waterlogged wood recovered from marine environments may contain high levels of salts, which must be removed from the waterlogged wood to prevent further damage on drying. This can be done by a desalination process. Desalination is often completed in bath changes using clean water. Sometimes disinfectants (fungicides or algaecides) are added to prevent the development of damaging organisms. However, the most commonly used and recommended because of its lesser toxicity is a mixture of boric acid and borax. The desalination process takes a long period of time and is necessary that the water is changed until the concentration of excreted of soluble salts reach its maximum.
Sources: en.wikipedia.org
== Biochemistry == LTB4 is a leukotriene involved in inflammation. It is produced from leukocytes in response to inflammatory mediators and is able to induce the adhesion and activation of leukocytes on the endothelium, allowing them to bind to and cross it into the tissue. In neutrophils, it is also a potent chemoattractant, and is able to induce the formation of reactive oxygen species and the release of lysosomal enzymes by these cells. It is synthesized by leukotriene-A4 hydrolase from leukotriene A4.
=== Expansion === Due to the success of the Selous Scouts, Walls directed in mid-1974 that it be expanded from three to six troops. This process was completed by December 1974, and included 50 former insurgents being added to the unit. A Reconnaissance Troop was formed in the second half of 1976 to conduct scouting operations in Mozambique and Zambia; this unit had a peak strength of twelve men. As part of the expansion of the Selous Scouts, the Rhodesian Army's Tracking Wing and Tracker Combat Unit were merged into it during 1974. The Tracking Wing became the Selous Scouts' Training Troop. The Selous Scouts continued to deliver training in tracking and trackers for the remainder of the war, with this forming a cover for the unit's actual role. The Tracker Combat Unit was made up of white reservists; while these men were not suitable for Selous Scouts operations, they were retained to help provide cover. These changes reduced the effectiveness of the Rhodesian Army's tracking capabilities. The size of the Selous Scouts increased further over time, and eventually reached 1,800 men. Many of these were territorial soldiers who were not permanently attached. The rapid expansion of the Selous Scouts led to a drop in the quality of its personnel, which reduced the effectiveness of pseudo operations. This in turn caused the unit to increasingly undertake offensive operations where it directly attacked insurgents rather than gathered intelligence on them.
Amorphous selenium has a low melting point, high vapor pressure, and uniform structure. These three properties allow quick and easy deposition of large-area uniform films with a thickness up to 1 mm at a rate of 1–5 μm/min. Their uniformity and lack of grain boundaries, which are intrinsic to polycrystalline materials, improve the X-ray image quality. Meanwhile the large area is essential for scanning the human body or luggage items. Selenium is less toxic than many compound semiconductors that contain arsenic or heavy metals such as mercury or lead. The mobility in applied electric field is sufficiently high both for electrons and holes, so that in a typical 0.2 mm thick device, c. 98% of electrons and holes produced by X-rays are collected at the electrodes without being trapped by various defects. Consequently, device sensitivity is high, and its behavior is easy to describe by simple transport equations.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.